Zacks: Analysts Expect AveXis, Inc. (AVXS) to Post -$1.51 EPS
Wall Street analysts expect that AveXis, Inc. (NASDAQ:AVXS) will announce earnings of ($1.51) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for AveXis’ earnings. The lowest EPS estimate is ($1.91) and the highest is ($0.69). AveXis posted earnings per share of ($0.92) during the same quarter last year, which would indicate a negative year over year growth rate of 64.1%. The business is scheduled to report its next earnings results on Thursday, March 15th.
According to Zacks, analysts expect that AveXis will report full-year earnings of ($6.23) per share for the current financial year, with EPS estimates ranging from ($6.61) to ($5.36). For the next financial year, analysts expect that the firm will post earnings of ($5.92) per share, with EPS estimates ranging from ($7.33) to ($2.90). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for AveXis.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same quarter in the previous year, the firm posted ($0.87) earnings per share.
In other AveXis news, VP Andrew F. Knudten sold 2,000 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $94.48, for a total transaction of $188,960.00. Following the sale, the vice president now directly owns 7,000 shares of the company’s stock, valued at approximately $661,360. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $101.46, for a total value of $1,521,900.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,340 shares of company stock worth $5,172,298. 18.60% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC grew its position in AveXis by 13.1% during the 2nd quarter. FMR LLC now owns 4,705,433 shares of the company’s stock worth $386,598,000 after purchasing an additional 544,475 shares during the period. BlackRock Inc. grew its position in AveXis by 34.7% during the 2nd quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock worth $189,069,000 after purchasing an additional 592,843 shares during the period. Vanguard Group Inc. grew its position in AveXis by 31.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock worth $129,419,000 after purchasing an additional 380,396 shares during the period. Janus Henderson Group PLC grew its position in AveXis by 52.2% during the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock worth $99,363,000 after purchasing an additional 352,456 shares during the period. Finally, State Street Corp grew its position in shares of AveXis by 104.2% during the 2nd quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after acquiring an additional 510,189 shares during the period. 92.88% of the stock is currently owned by institutional investors.
Shares of AveXis (NASDAQ:AVXS) opened at $93.50 on Wednesday. AveXis has a twelve month low of $44.68 and a twelve month high of $108.27.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.